Search hospitals > Ohio > Columbus
Columbus Oncology and Hematology Associates Inc
Claim this profileColumbus, Ohio 43214
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Stomach Cancer
Conducts research for Non-Small Cell Lung Cancer
221 reported clinical trials
8 medical researchers
Summary
Columbus Oncology and Hematology Associates Inc is a medical facility located in Columbus, Ohio. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Non-Small Cell Lung Cancer and other specialties. Columbus Oncology and Hematology Associates Inc is involved with conducting 221 clinical trials across 381 conditions. There are 8 research doctors associated with this hospital, such as Timothy D. Moore, Aine E. Clements, Anitha S. Nallari, and Chaoyang Li.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center6 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
Aine E. ClementsOhioHealth Mansfield Hospital2 years of reported clinical research
Studies Endometrial Cancer
Studies Ovarian Cancer
7 reported clinical trials
32 drugs studied
Anitha S. NallariColumbus Oncology and Hematology Associates1 year of reported clinical research
Studies Skin Cancer
Studies Breast Cancer
4 reported clinical trials
10 drugs studied
Chaoyang LiDelaware Health Center-Grady Cancer Center9 years of reported clinical research
Studies Skin Cancer
Studies Cutaneous Melanoma
2 reported clinical trials
8 drugs studied
Clinical Trials running at Columbus Oncology and Hematology Associates Inc
Breast Cancer
Skin Cancer
Bladder Cancer
Lung Cancer
Ovarian Cancer
Breast cancer
Cancer
Cutaneous Melanoma
Bladder Carcinoma
Multiple Myeloma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Columbus Oncology and Hematology Associates Inc?
Columbus Oncology and Hematology Associates Inc is a medical facility located in Columbus, Ohio. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Non-Small Cell Lung Cancer and other specialties. Columbus Oncology and Hematology Associates Inc is involved with conducting 221 clinical trials across 381 conditions. There are 8 research doctors associated with this hospital, such as Timothy D. Moore, Aine E. Clements, Anitha S. Nallari, and Chaoyang Li.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.